Side Effects of cabergoline: A Synthesis of Findings from 26 Studies

  1. Home
  2. Side Effects of cabergoline
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of cabergoline: A Synthesis of Findings from 26 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of cabergoline: A Synthesis of Findings from 26 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Research Findings

Cabergoline is a dopamine agonist used to treat prolactinomas and Parkinson's disease. However, cabergoline is known to cause several side effects. These side effects include cardiac valvular fibrosis, pleural, pericardial and retroperitoneal fibrosis, impulse control disorders, and risks secondary to significantly decreased tumor volume. 3

Cabergoline may improve depressive symptoms in the treatment of Parkinson's disease. 6

Cabergoline can induce mood swings in the treatment of prolactinomas. 11

Cabergoline is effective in patients with prolactinomas who are resistant or intolerant to bromocriptine. 18

Cabergoline may be more effective than bromocriptine in the treatment of prolactinomas. 21

Cabergoline can be administered intravaginally in the treatment of prolactinomas and can overcome intolerance to dopamine agonists. 13

Cabergoline can maintain normal GH and IGF-I levels after long-term treatment in patients with acromegaly. 19

Cabergoline may be less likely to cause motor complications than levodopa in the treatment of early Parkinson's disease. 5

Cabergoline can induce mania in patients with bipolar I disorder. 12

Cabergoline can be safely switched from other dopamine agonists overnight. 20

Cabergoline can cause cardiac valvular disease in patients with Parkinson's disease. 9

Cabergoline can cause impulse control disorders, especially compulsive buying, binge eating, and hypersexuality, in the treatment of prolactinomas. 1

Cabergoline can induce pathological gambling in patients with Parkinson's disease. 10

Cabergoline can cause cardiopulmonary fibrotic side effects in patients with Parkinson's disease. 8

Cabergoline is the most widely used dopamine agonist in the treatment of prolactinomas. 22

Cabergoline can cause pulmonary side effects in the treatment of prolactinomas. 2

Cabergoline is one of three dopamine agonists, bromocriptine, cabergoline, and quinagolide, used in the treatment of hyperprolactinemia and prolactinomas. 23

With long-term use of cabergoline in the treatment of prolactinomas, an attempt to discontinue dopamine agonist may be possible in some patients, and long-term remission appears more likely in patients who achieve clinical, biochemical, and imaging remission criteria after 2 years of therapy. 26

Reasons for Side Effects

Cabergoline inhibits prolactin secretion by acting on dopamine receptors. Dopamine is involved in the reward system in the brain, and therefore cabergoline may cause side effects such as impulse control disorders. 10

Common Side Effects

Cardiac Valvular Disease

Cabergoline can cause cardiac valvular disease. Cardiac valvular disease is a condition where the heart's valves do not function properly. 3 9

Pleural, Pericardial and Retroperitoneal Fibrosis

Cabergoline can cause pleural, pericardial and retroperitoneal fibrosis. Fibrosis is a condition where tissue becomes hard. 3

Impulse Control Disorders

Cabergoline can cause impulse control disorders. Impulse control disorders are conditions where people are unable to control their impulsive behaviors. 3 10 1

Mood Swings

Cabergoline can cause mood swings. Mood swings are a condition where people experience unstable moods. 11

Pulmonary Side Effects

Cabergoline can cause pulmonary side effects. 2

Countermeasures for Side Effects

Cardiac Valvular Disease

Regular heart examinations are important for the prevention of cardiac valvular disease. 9

Pleural, Pericardial and Retroperitoneal Fibrosis

Discontinuation of cabergoline use is important for the prevention of pleural, pericardial and retroperitoneal fibrosis. 3

Impulse Control Disorders

Discontinuation of cabergoline use is important for the prevention of impulse control disorders. 3

Mood Swings

Discontinuation of cabergoline use is important for the prevention of mood swings. 11

Pulmonary Side Effects

Regular pulmonary examinations are important for the prevention of pulmonary side effects. 2

Comparison between Studies

Similarities in Studies

Many studies have shown that cabergoline can cause side effects such as cardiac valvular disease, pleural, pericardial and retroperitoneal fibrosis, and impulse control disorders. 3 10 1 9

Differences in Studies

Side effects of cabergoline can vary from patient to patient. Some patients may experience severe side effects such as cardiac valvular disease. 3 9

Precautions for Real-Life Applications

It is important to consult a doctor about the risks of side effects before using cabergoline. 3 10 1 9

Regular heart examinations are necessary because cabergoline can cause side effects such as cardiac valvular disease. 9

Limitations of Current Research

Research on the side effects of cabergoline is still insufficient. In particular, there is little research on long-term side effects. 3

Directions for Future Research

Research on the long-term side effects of cabergoline is needed. 3

The development of new treatments to reduce the side effects of cabergoline is also needed. 3

Conclusion

Cabergoline is an effective drug for the treatment of prolactinomas and Parkinson's disease, but it can cause side effects such as cardiac valvular disease, pleural, pericardial and retroperitoneal fibrosis, and impulse control disorders. 3 10 1 9

It is important to consult a doctor about the risks of side effects before using cabergoline. 3 10 1 9

Literature analysis of 26 papers
Positive Content
20
Neutral Content
1
Negative Content
5
Article Type
0
1
1
7
23
1.

Binge Eating and Compulsive Buying During Cabergoline Treatment for Prolactinoma: A Case Report.

Author: Correa E CastroAna Carolina, de AraujoAndressa Alexandre, BotelhoMariana Coelho, NascimentoJoão Bosco, de SouzaRafaela Marchon, GadelhaMonica Roberto, NardiAntonio E, ViolanteAlice Helena Dutra

Prolactinoma treatment
Impulsivity disorders

This case report highlights the potential for compulsive buying, binge eating, and hypersexuality to develop in prolactinoma patients treated with cabergoline, a dopamine agonist. Although these behaviors have been reported before, this case emphasizes the importance of regular psychiatric evaluations during cabergoline treatment, particularly for patients receiving long-term therapy.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Language : English

3.

The risks of medical treatment of prolactinoma.

Author: CastinettiFrederic, AlbarelFrederique, AmodruVincent, CunyThomas, DufourHenry, GraillonThomas, MorangeIsabelle, BrueThierry

Prolactinoma treatment
Addictive behavior
Cardiac valvular fibrosis
Fibrosis
Tumor shrinkage risks

Cabergoline is a dopamine agonist used to treat prolactinomas. This review summarizes the less common but important side effects of cabergoline, including cardiac valvular fibrosis, fibrosis in other organs, addictive/compulsive behaviors, and risks related to tumor volume decrease.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

4.

Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas.

Author: AthanasouliaA P, SieversC, IsingM, BrockhausA C, YassouridisA, StallaG K, UhrM

Prolactin adenoma treatment
Central side effects

This study investigated the relationship between central side effects of dopamine agonists used for prolactinomas and Parkinson's disease and the P-glycoprotein (P-gp) encoded by the ABCB1 gene, which controls drug passage through the blood-brain barrier.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

6.

[Choosing a dopamine agonist in Parkinson's disease].

Author: BoguckiAndrzej, GajosAgata

Antidepressant activity
Parkinson's disease treatment
Fibrosis
Oedema
Valvular heart disease

The article discusses the increasing use of dopamine agonists in Parkinson's disease, comparing their efficacy, side effects, and suitability for different stages of the disease.

English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : Polish

7.

Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism.

Author: LarramendyCelia, TaraviniIrene R E, SaboridoMariano D, FerrarioJuan E, MurerMario G, GershanikOscar S

Dyskinesias

D2 dopamine agonists are less prone to induce levodopa-induced dyskinesias than levodopa itself. This study found that pramipexole, a D2 agonist with a shorter half-life, was more likely to induce dyskinesias in rats pre-treated with levodopa. However, de novo treatment with D2 agonists was associated with a lower risk of dyskinesias.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

8.

Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinson's disease patients treated with cabergoline.

Author: DhawanV, MedcalfP, StegieF, JacksonG, BasuS, LuceP, OdinP, ChaudhuriK Ray

Parkinson's disease treatment
Cardiac valvulopathy
Fibrotic side effects

Cardiac valvulopathy is associated with the use of pergolide in Parkinson's disease (PD), however there is limited evidence to support the association of cabergoline with fibrotic side effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

9.

[Two cases of patients with Parkinson's disease developing valvular heart disease while taking cabergoline].

Author: SatoTakashi, KikuchiAkio, OnoueNoriko, HiramotoTetuya, OumiMikio, OnoderaJunichi

Treats Parkinson's
Heart failure
Valvular heart disease

Two patients with valvular heart disease who were taking cabergoline for Parkinson's disease were reported.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : Japanese

10.

[Pathological gambling induced by dopamine agonists].

Author: GahrM, ConnemannB J, Schönfeldt-LecuonaC J

Pathological gambling

Pathological gambling, a known side effect of dopaminergic therapy in Parkinson's disease patients, can also occur in patients treated with dopamine agonists for other conditions. Two cases are reported: one with ropinirole for restless legs syndrome and another with cabergoline for prolactinoma, both experiencing significant gambling issues.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : German

12.

Cabergoline can induce mania with psychotic features in bipolar I disorder: a case report.

Author: RoveraChiara, CremaschiLaura, ThanjuAmod, FiorentiniAlessio, MauriMassimo Carlo, SeratiMarta, LindenmayerJean Pierre, AltamuraA Carlo

Prolactin reduction
Psychosis

Cabergoline is generally a safe and effective method of reducing prolactin levels but it may be associated with psychiatric side effects, including psychotic features.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
LetterA written message for communication and exchange of information between individuals.

Language : English

13.

How to manage intolerance to dopamine agonist in patients with prolactinoma.

Author: StumpfMatheo Augusto Morandi, PinheiroFelipe Moura Maia, SilvaGilberto Ochman, CescatoValter Angelo Sperling, MusolinoNina Rosa Castro, Cunha-NetoMalebranche Berardo Carneiro, GlezerAndrea

Prolactinoma treatment
Drug intolerance

Dopamine agonists (DA) are the gold-standard for prolactinoma and hyperprolactinemia treatment, but they can cause side effects such as nausea, vomiting, and fatigue. This review discusses DA intolerance and presents a case report concerning the use of intravaginal cabergoline.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

18.

[Usefulness of cabergoline in patients with prolactinemia and resistant or intolerant to bromocriptine].

Author: Velázquez-ChávezFrancisco Javier, Tapia-GonzálezMaría de Los Angeles, González-BárcenaDavid

Prolactinoma treatment

This study evaluated the response to cabergoline (CBG) in patients who were intolerant or resistant to bromocriptine (BCE) for the treatment of prolactinomas.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : Spanish

19.

Remission of acromegaly following long-term therapy with cabergoline: report of two cases.

Author: VerhelstJohan A, AbramsPascale J, AbsRoger

Acromegaly remission
Normal GH/IGF-I levels
Decreased libido
Stomach pain

This study describes two acromegalic patients who responded well to cabergoline treatment but surprisingly maintained normal GH and IGF-I levels after discontinuing therapy. This suggests that in some cases, acromegaly may be effectively treated with cabergoline and remission may be maintained even after cessation of therapy.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

20.

Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.

Author: LinazasoroGurutz,

Clinical improvement
Abdominal pain
Dizziness
Dyskinesias
Dyspnea
Face edema
Hallucinations
Respiratory arrest
Vascular problems

Overnight switching from pergolide, ropinirole, and pramipexole to cabergoline was safe and showed clinical improvement.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

21.

Retrospective comparison of cabergoline and bromocriptine effects in hyperprolactinemia: a single center experience.

Author: ArducA, GokayF, IsikS, OzuguzU, AkbabaG, TutuncuY, BerkerD, KucuklerF K, AydinY, GulerS

Prolactin level normalization
Tumor size reduction

The efficacy of cabergoline and bromocriptine was compared in patients with hyperprolactinemia.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

22.

The safety of treatments for prolactinomas.

Author: AuriemmaRenata S, GrassoLudovica F S, PivonelloRosario, ColaoAnnamaria

Prolactinoma treatment
Cardiac valvulopathy

Dopamine agonists (DAs), particularly cabergoline (CAB), are the mainstay treatment for prolactinomas. While DAs are generally safe and well-tolerated, a potential risk of clinically relevant cardiac valvulopathy exists with CAB, although it is rare in patients with prolactinomas.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

23.

The efficacy and safety of quinagolide in hyperprolactinemia treatment: A systematic review and meta-analysis.

Author: ZengYanyang, HuangQingliang, ZouYunzhi, TanJiacong, ZhouWu, LiMeihua

Hyperprolactinemia treatment

Quinagolide (CV) is a dopamine agonist used to treat hyperprolactinemia and prolactinoma. This review examines the efficacy and safety of CV based on available studies.

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

24.

Medical therapy of Cushing's disease: where are we now?

Author: AlexandrakiKrystallenia I, GrossmanAshley B

Cushing's disease treatment
Side effects

Surgery is the current 'gold standard' treatment for Cushing's disease, but no effective drug that directly targets the adrenocorticotropin-secreting pituitary adenoma has been found. Current medical therapies include inhibitors of adrenal steroidogenesis, adrenolytic agents, and compounds with neuromodulatory properties.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.